Medincell stock rebounds but remains oversold, RSI fallen to 27
The Montpellier-based biopharmaceutical company is regaining ground at the close of trading on Thursday, September 17, 2026, advancing in a Paris market that is also oriented upwards. The rebound remains fragile, however, given the downward pressure accumulated since summer, which has driven the stock away from its three moving averages.
A rebound of 2.13% that only recovers a fraction of the quarterly decline of 21%
Medincell gains 2.13% during the session, trading at 22.06 €, while the CAC 40 advances 0.59% and the SBF 120 rises 0.58%. The stock records one of the best performances of the SBF 120 during the session. This rebound comes after several weeks of decline: over one month, the stock still loses 8.47%, and the three-month performance stands at -21.27%. The day's advance, welcome as it may be, thus only partially offsets this quarterly decline.
Over one year, however, the stock remains in positive territory with a gain of 11.25%, which shows that the longer-term momentum is not yet broken. The macro context is also weighing on all growth stocks: the Fed raised its rates by 25 basis points to 3.75%-4.00% today, the first hike since 2023, while American inflation remains above its target. More restrictive financial conditions tend to penalize biopharmaceutical companies whose cash flows are still distant.
An RSI in deep oversold territory at 27, with three moving averages as ceilings to reclaim
The technical configuration of Medincell remains under pressure despite today's rebound. The stock trades below its three moving averages: the MA20 at 23.32 €, the MA50 at 24.66 € and the MA200 at 25.03 €, representing respective gaps of 5.40%, 10.54% and 11.87% above the current price. These three levels form a triple ceiling that the stock will need to break through to regain positive momentum. The RSI at 27 reflects a marked oversold configuration, consistent with the scale of the recent decline.
Such a level indicates that selling pressure has been largely exercised, without guaranteeing an immediate turnaround. On the key levels side, the support threshold at 21.40 € remains the reference to monitor in case of a pullback, while the resistance at 25.42 € represents the first significant obstacle beyond the moving averages. The appointment of Dr. Edna Venneker as medical director, announced on September 2, provides substance without short-term impact on the stock price. The company is also advancing several regulatory files with the FDA and EMA, which constitutes a medium-term horizon for the stock.
